← Back to Clinical Trials
Recruiting NCT06570421

NCT06570421 24-months Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06570421
Status Recruiting
Phase
Sponsor Stimvia s.r.o.
Condition Parkinson Disease
Study Type INTERVENTIONAL
Enrollment 20 participants
Start Date 2024-07-19
Primary Completion 2026-07

Trial Parameters

Condition Parkinson Disease
Sponsor Stimvia s.r.o.
Study Type INTERVENTIONAL
Phase N/A
Enrollment 20
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-07-19
Completion 2026-07
Interventions
Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study investigates the long-term safety and tolerability of home peroneal eTNM® therapy using the URIS I™ device in subjects with Parkinson's disease (PD) or Essential Tremor (ET). Previously, a 6-week open-label pilot study with 24 PD or ET patients demonstrated that home-based peroneal eTNM® is safe, well-tolerated, and has a high adherence rate of over 90%. No treatment-related adverse events were observed. Although the pilot study was not designed to prove efficacy, it suggested positive effects on tremor, with improvements sustained for weeks after treatment. This extension study aims to further evaluate the long-term safety, tolerability, and efficacy of peroneal eTNM® in PD and ET patients.

Eligibility Criteria

Inclusion Criteria: * Has completed participation in study TS004-PD * Competent and willing to provide written, informed consent to participate in the study. * Stable dose of any chronic medications, if applicable, for 30 days prior to study entry * Willing to comply with study protocol requirements. * Subject agrees not to participate in another study from 30 days prior the baseline visit until the final study visit. * For subjects with PD: * Bradykinesia in "on" period based on clinical assessment * Rigidity in "on" period based on clinical assessment * Hand/arm exhibiting tremor (resting and/or intentional and/or postural) ≥ grade 1 as assessed by the MDS-UPDRS tremor score in "on" period * For subjects with ET: * Visible hand/arm and/or foot/leg tremor (resting and/or intentional and/or postural) ≥ grade 1 as assessed by the TETRAS Exclusion Criteria: * Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator * Suspected or diagnosed epileps

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology